BLIP-II is a highly potent inhibitor of Klebsiella pneumoniae carbapenemase (KPC-2)

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3398-3401

  Brown, Nicholas G ^a,b   Chow, Dar Chone ^a   Palzkill, Timothy ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BETA LACTAMASE INHIBITORY PROTEIN II; KLEBSIELLA PNEUMONIAE CARBAPANEMASE 2; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84879019120     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00215-13     Document Type: Article

References (30)

1. Livermore DM. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14:413-420. (Pubitemid 44233298)
2. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 360:439-443.
3. Livermore DM. 2012. Fourteen years in resistance. Int. J. Antimicrob. Chemother. 39:283-294.
4. Bush K, Fisher JF. 2011. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu. Rev. Microbiol. 65:455-478.
5. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. Antimicrob. Agents Chemother. 55:4943-4960.
6. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm. Trends Mol. Med. 18:263-272.
7. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol. 19:588-595.
8. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45:1151-1161. (Pubitemid 32230996)
9. KPC gene. Antimicrob. Agents Chemother. 55:1257-1263. (Pubitemid 351521985)
10. KPC-2 gene. Emerg. Infect. Dis. 16:1349-1356.
11. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPCproducing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob. Agents Chemother. 53:3365-3370.
12. Mathers AJ, Cox HL, Kitchel B, Bonatti H, Brassinga AKC, Carroll J, Scheld WM, Hazen KC, Sifri CD. 2011. Molecular dissection of an outbreak of carbapenem-resistant Enterobacteriaceae reveals intergenus KPC carbapenemase transmission through a promiscuous plasmid. mBio 2(6):e00204-11. doi:10.1128/mBio.00204-11.
13. Doran JL, Leskiw BK, Aippersbach S, Jensen SE. 1990. Isolation and characterization of a β-lactamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene. J. Bacteriol. 172:4909-4918. (Pubitemid 20281936)
14. Brown AG. 1986. Clavulanic acid, a novel β-lactamase inhibitor - a case study in drug discovery and development. Drug Des. Deliv. 1:1-21. (Pubitemid 17161560)
15. Neu HC, Fu KP. 1978. Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrob. Agents Chemother. 14:650-655. (Pubitemid 9045849)
16. Gretes M, Lim DC, de Castro L, Jensen S, Kang SG, Lee KJ, Strynadka NCJ. 2009. Insights into positive and negative requirements for proteinprotein interactions by crystallographic analysis of the β-lactamase inhibitory proteins BLIP, BLIP-I, and BLP. J. Mol. Biol. 389:289-305.
17. Kang SG, Park HU, Lee HS, Kim HT, Lee KJ. 2000. New beta-lactamase inhibitory protein (BLIP-I) from Streptomyces exfoliatus SMF19 and its roles on the morphological differentiation. J. Biol. Chem. 275:16851-16856. (Pubitemid 30398920)
18. Lim D, Park HU, De Castro L, Kang SG, Lee HS, Jensen S, Lee KJ, Strynadka NCJ. 2001. Crystal structure and kinetic analysis of β-lactamase inhibitor protein-II in complex with TEM-1 β-lactamase. Nat. Struct. Biol. 8:848-852. (Pubitemid 32923602)
19. Brown NG, Chow D-C, Sankaran B, Zwart P, Prasad BV, Palzkill T. 2011. Analysis of the binding forces driving the tight binding between β-lactamase inhibitory protein II (BLIP-II) and class A β-lactamases. J. Biol. Chem. 286:32723-32725.
20. Brown NG, Palzkill T. 2010. Identification and characterization of betalactamase inhibitor protein-II (BLIP-II) interactions with beta-lactamases using phage display. Protein Eng. Des. Sel. 23:469-478.
21. Zhang Z, Palzkill T. 2003. Determinants of binding affinity and specificity for the interaction of TEM-1 and SME-1 β-lactamase with β-lactamase inhibitory protein. J. Biol. Chem. 278:45706-45712. (Pubitemid 37432713)
22. Zhang Z, Palzkill T. 2004. Dissecting the protein-protein interface between beta-lactamase inhibitory protein and class A beta-lactamases. J. Biol. Chem. 279:42860-42866. (Pubitemid 39372175)
23. Hanes MS, Jude KM, Berger JM, Bonomo RA, Handel TM. 2009. Structural and biochemical characterization of the interaction between KPC-2 beta-lactamase and beta-lactamase inhibitor protein. Biochemistry 48:9185-9193.
24. Schreiber G, Haran G, Zhou HX. 2009. Fundamental aspects of proteinprotein association kinetics. Chem. Rev. 109:839-860.
25. Wassaf D, Kuang G, Kopacz K, Wu Q-L, Nguyen Q, Toews M, Cosic J, Jacques J, Wiltshire S, Lambert J, Pazmany CC, Hogan S, Ladner RC, Nixon AE, Sexton DJ. 2006. High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. Anal. Biochem. 351: 241-253.
26. Schreiber G, Fersht AR. 1996. Rapid, electrostatically assisted association of proteins. Nat. Struct. Biol. 3:427-431. (Pubitemid 26139441)
27. Schreiber G, Fersht AR. 1993. The interaction of barnase with its polypeptide inhibitor barstar studied by protein engineering. Biochemistry 32:5145-5150. (Pubitemid 23162083)
28. Koren E, Torchilin VP. 2012. Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18:385-393.
29. Cohen O, Kronman C, Lazar A, Velan B, Shafferman A. 2007. Controlled concealment of exposed clearance and immunogenic domains by site-specific polyethylene glycol attachment to acetylcholinesterase hypolysine mutants. J. Biol. Chem. 282:35491-35501. (Pubitemid 350277096)
30. Veronese FM, Mero A. 2008. The impact of PEGylation on biological therapies. BioDrugs 22:315-329.